{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T15:56:13Z","timestamp":1767974173178,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,12]],"date-time":"2015-02-12T00:00:00Z","timestamp":1423699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journalofclinicalvirology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.jcv.2015.02.005","type":"journal-article","created":{"date-parts":[[2015,2,9]],"date-time":"2015-02-09T09:56:03Z","timestamp":1423475763000},"page":"50-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort"],"prefix":"10.1016","volume":"65","author":[{"given":"Samantha J.","family":"Shepherd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamer","family":"Abdelrahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alasdair R.","family":"MacLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma C.","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celia","family":"Aitken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rory N.","family":"Gunson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2015.02.005_bib0005","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2015.02.005_bib0010","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.02.005_bib0015","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telparevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.02.005_bib0020","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.02.005_bib0025","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2015.02.005_bib0030","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","article-title":"Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial","volume":"146","author":"Forns","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcv.2015.02.005_bib0035","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2015.02.005_bib0040","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"NEJM"},{"key":"10.1016\/j.jcv.2015.02.005_bib0045","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"NEJM"},{"key":"10.1016\/j.jcv.2015.02.005_bib0050","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.antiviral.2005.12.003","article-title":"Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH","volume":"70","author":"Tong","year":"2006","journal-title":"Antiviral Res."},{"key":"10.1016\/j.jcv.2015.02.005_bib0055","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/hep.21781","article-title":"Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients","volume":"46","author":"Kieffer","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2015.02.005_bib0060","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis virus genotype and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcv.2015.02.005_bib0065","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435","volume":"54","author":"Lenz","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2015.02.005_bib0070","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","article-title":"Hepatitis C virus resistance to protease inhibitors","volume":"55","author":"Halfon","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jcv.2015.02.005_bib0075","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/jvh.12230","article-title":"Importance of HCV genotype 1 subtypes for drug resistance and response to therapy","volume":"21","author":"Wyles","year":"2014","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.jcv.2015.02.005_bib0080","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0140-6736(14)60807-2","article-title":"QUEST for a cure for hepatitis C virus: the end is in sight","volume":"384","author":"Ghany","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2015.02.005_bib0085","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.antiviral.2007.11.010","article-title":"Characterisation of resistance mutations against HCV ketoamide protease inhibitors","volume":"77","author":"Tong","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.jcv.2015.02.005_bib0090","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/hep.23192","article-title":"Characterisation of resistance to protease inhibitor boceprevir in hepatitis C virus-infected patients","volume":"50","author":"Susser","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2015.02.005_bib0095","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1128\/AAC.00777-10","article-title":"Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors","volume":"54","author":"Bae","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2015.02.005_bib0100","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/jac\/dkr581","article-title":"Naturally occurring hepatitis C virus (HCV) NS3\/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy","volume":"67","author":"Vicenti","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2015.02.005_bib0105","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/JVI.02294-12","article-title":"Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-na\u00efve patients prior to treatment","volume":"87","author":"Bartels","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.jcv.2015.02.005_bib0110","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2013.04.018","article-title":"Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in hepatitis C virus genotypes 1a, 2b and 3a","volume":"99","author":"Palanisamy","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.jcv.2015.02.005_bib0115","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jcv.2014.06.023","article-title":"Patients eligible for treatment with simeprevir in a French center","volume":"61","author":"Morel","year":"2014","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2015.02.005_bib0120","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2007.07.033","article-title":"Changing epidemiology of hepatitis C virus infection in Europe","volume":"48","author":"Esteban","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jcv.2015.02.005_bib0125","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/591141","article-title":"Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3. 4A protease inhibitors in treatment-naive subjects","volume":"198","author":"Bartels","year":"2008","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcv.2015.02.005_bib0130","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.3851\/IMP1900","article-title":"NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1\u20135","volume":"16","author":"Vallet","year":"2011","journal-title":"Antiviral Ther."},{"key":"10.1016\/j.jcv.2015.02.005_bib0135","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1097\/QAD.0b013e328363b1f9","article-title":"Natural NS3 resistance polymorphism occur frequently prior to treatment in HIV-positive patients with acute hepatitis C","volume":"27","author":"Leggewie","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2015.02.005_bib0140","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1128\/AAC.01598-08","article-title":"GT-1a or GT-1b subtype-specific resistance profiles for heaptitis C virus inhibitors telaprevir and HCV-796","volume":"53","author":"McGown","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2015.02.005_bib0145","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","article-title":"Update on hepatitis C virus resistance to direct-acting antiviral agents","volume":"108","author":"Proveda","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.jcv.2015.02.005_bib0150","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.virol.2013.06.029","article-title":"Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies","volume":"444","author":"Barnard","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.jcv.2015.02.005_bib0155","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2010.10.056","article-title":"Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus","volume":"140","author":"Shimakami","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcv.2015.02.005_bib0160","doi-asserted-by":"crossref","first-page":"e34372","DOI":"10.1371\/journal.pone.0034372","article-title":"Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials","volume":"7","author":"Kieffer","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jcv.2015.02.005_bib0165","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1128\/AAC.01578-13","article-title":"In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir","volume":"57","author":"Jiang","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2015.02.005_bib0170","first-page":"1","article-title":"Clinical implications of detectable baseline hepatitis C virus-genotype 1 NS3\/4A-protease variants on the efficacy of boceprevir combined with perinterferon\/ribavirin","volume":"1","author":"Howe","year":"2014","journal-title":"OFID"},{"key":"10.1016\/j.jcv.2015.02.005_bib0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jcv.2014.06.013","article-title":"Deep sequencing: becoming a critical tool in clinical virology","volume":"61","author":"Quinones-Mateu","year":"2014","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2015.02.005_bib0180","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.virusres.2013.08.001","article-title":"Extent of HCV NS3 protease variability and resistance-associated mutations assessed by next generation sequencing in HCV monoinfected and HIV\/HCV coinfected patients","volume":"177","author":"Bartolini","year":"2013","journal-title":"Virus Res."},{"key":"10.1016\/j.jcv.2015.02.005_bib0185","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1128\/AAC.03466-14","article-title":"Hepatitis C virus NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV\/HIV coinfection","volume":"58","author":"Jabara","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2015.02.005_bib0190","unstructured":"European Association for the Study of the Liver, 2014. EASL Recommendations on treatment of Hepatitis C. http:\/\/files.easl.eu\/easl-recommendations-on-treatment-of-hepatitis-C.pdf."},{"key":"10.1016\/j.jcv.2015.02.005_bib0195","series-title":"49th Annual Meeting of the European Association for the Study of the Liver, abstract O7","article-title":"Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 prior null responders with Metavir F0-2: COSMOS study subgroup analysis","author":"Sulkowski","year":"2014"},{"key":"10.1016\/j.jcv.2015.02.005_bib0200","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-na\u00efve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial","volume":"383","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2015.02.005_bib0205","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.antiviral.2014.02.011","article-title":"Antiviral therapy of hepatitis C in 2014: do we need resistance testing?","volume":"105","author":"Schneider","year":"2014","journal-title":"Antiviral Res."}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653215000529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653215000529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T06:21:25Z","timestamp":1537856485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653215000529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":41,"alternative-id":["S1386653215000529"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2015.02.005","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2015.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2015 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}